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Background: Aclidinium is a novel, long-acting muscarinic antagonist indicated for mainte-
nance treatment of COPD.
Methods: In this 52-week, parallel-group, double-blind study, patients with moderate-to-
severe COPD were randomized (1:1) to receive aclidinium twice-daily (BID) 200 mg or 400 mg
via a novel, dry powder inhaler (Genuair/Pressair) [Registered trademarks of Almirall, SA,
Barcelona, Spain for use within the European Union, Iceland, Norway, and Switzerland as Gen-
uair and within the United States as Pressair]. Safety, the primary objective, was assessed
via adverse events (AEs), clinical laboratory tests, vital signs, and 12-lead electrocardiograms.
Efficacy was evaluated using spirometry, SGRQ, and rescue medication use.
Results: A total of 605 patients were randomized in the study. The percentage of patients re-
porting any treatment-emergent AE (TEAE) was comparable between groups; most TEAEs were
mild or moderate. Anticholinergic TEAEs were reported by low percentages of patients in
either treatment group (dry mouth: 200 mg, 1.3%; 400 mg, 2.7%; constipation: 200 mg, 2.9%;
400 mg, 1.7%). Cardiac TEAEs were also reported by a low percentage of patients (<2% for
any event in any group) and did not appear to be dose dependent. There were no clinically
relevant abnormalities in other safety outcomes. Both aclidinium 200 mg and 400 mg resulted
in improvements from baseline to Week 52 in FEV1, with numerically greater increases
observed with the higher dose. Clinically important improvements in SGRQ scores and a2 622 2204; fax: þ1 562 633
A.F. Gelb).
3 Elsevier Ltd. All rights reserved.
3.07.001
1958 A.F. Gelb et al.reduction in rescue medication use were observed throughout the study for both doses.
Conclusions: Long-term treatment with aclidinium 200 mg or 400 mg BID was well tolerated,
with sustained benefits in lung function and health status in patients with COPD throughout
the 1-year study.
Clinical trial registration number: NCT01044459.
ª 2013 Elsevier Ltd. All rights reserved.1 Registered trademarks of Almirall, SA, Barcelona, Spain for use
within the European Union, Iceland, Norway, and Switzerland as
Genuair and within the United States as Pressair.Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death in the world [1] and incurs a sub-
stantial economic and social burden due to increased
healthcare expenditures and lost work productivity [2e4].
Inhaled long-acting bronchodilators are central to the
reduction of symptoms and improvement of health status
and lung function in patients with COPD. These therapeutic
options are therefore recommended by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines for
effective disease management [5]
Aclidinium is a novel inhaled long-acting muscarinic
antagonist (LAMA) indicated for maintenance treatment of
COPD. Due to the heterogeneity of COPD [6] and prevalence
of polypharmacy among COPD patients [7,8], the avail-
ability of aclidinium as an additional effective therapeutic
option with a good safety profile and reduced potential for
drug interactions would be valuable for this patient
population.
Clinical studies have previously demonstrated that
twice-daily (BID) aclidinium 200 mg and 400 mg provided
bronchodilation over a 24-h period in patients with COPD,
with significantly improved lung function observed as early
as the first day of treatment that was sustained until study
end [9e12]. Significant reductions in breathlessness and
clinically significant improvements in health status have
also been reported with aclidinium BID treatment [10,11].
Aclidinium was also shown to be well tolerated in patients
with COPD, with safety profiles comparable between doses
and similar to that of placebo [9e12]. Furthermore, the
rapid plasma hydrolysis of aclidinium into inactive metab-
olites by butyrylcholinesterase without involvement of cy-
tochrome P450 or serum albumin suggests a reduced
potential for systemic side effects and a low likelihood of
drugedrug interactions involving aclidinium [13,14].
Various studies have thus demonstrated the efficacy and
safety of aclidinium in studies up to 6 months in duration.
As COPD is due to persistent airflow limitation in the lung
[15], effective disease management would ideally be ach-
ieved with a maintenance therapeutic option that is well
tolerated and maintains its efficacy over time. Assessing
the effects of long-term treatment with twice-daily acli-
dinium is therefore essential in comprehensively evaluating
its safety and efficacy profile. Here we report the results
from a 52-week, randomized, double-blind, multicenter,
parallel-group study with twice-daily aclidinium 200 mg and
400 mg in patients with moderate-to-severe COPD. The
primary objective of this study was to assess the long-term
safety and tolerability of aclidinium treatment. Secondary
evaluations included bronchodilator efficacy, health status,
and rescue medication use.Methods
Study design
This was a Phase 3, randomized, double-blind, parallel-
group study in patients with moderate-to-severe COPD
conducted in 106 centers in the United States and three
centers in Canada (NCT01044459). The study consisted of a
2-week run-in period prior to a 52-week double-blind
treatment period, with a follow-up telephone call 2
weeks after the last dose of study treatment. Eligible pa-
tients were randomized 1:1 to twice-daily aclidinium 200 mg
or 400 mg. Both doses were administered via a multidose,
dry powder inhaler (Genuair/Pressair)1. The study was
conducted according to International Conference on Har-
monisation/Good Clinical Practice guidelines and the
Declaration of Helsinki; the protocol was approved by the
Institutional Review Board at each study center. All pa-
tients gave written informed consent before participating
in any study procedures.Patient population
Male and female patients 40 years of age were eligible
provided that they were current or former smokers with a
smoking history of 10 pack-years and were diagnosed with
stable, moderate-to-severe expiratory airflow obstruction
according to GOLD guidelines [16] (postbronchodilator
forced expiratory volume in 1 s [FEV1]/forced vital capacity
[FVC] <70% and FEV1 30% and <80% predicted). Subjects
were excluded if they had a history of hypersensitivity re-
action or contraindications to the use of inhaled anticho-
linergics, experienced a COPD exacerbation requiring
hospitalization 3 months before screening, any respira-
tory tract infection or COPD exacerbation 6 weeks before
screening, any other clinically significant respiratory con-
dition (including asthma), or had clinically significant car-
diovascular conditions such as myocardial infarction or
newly diagnosed arrhythmia 6 months and 3 months
before screening, respectively, hospitalization within the
previous 12 months for heart failure, unstable angina, or
unstable arrhythmia that required changes in pharmaco-
logical therapy or other invention.
Use of albuterol and salbutamol as rescue medications
was permitted. Patients receiving long-acting beta2-agonist
(LABA)/inhaled corticosteroid (ICS) maintenance therapy
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component and maintained on the ICS component. The use
of other anticholinergics during the study was not
permitted. Other COPD medications, such as theophylline
and ICS, oral or parenteral corticosteroids (10 mg/day of
prednisone or 20 mg every other day) were only allowed if
treatment was stable 4 weeks prior to screening. Use of
rescue medication, theophylline, or ICS was discontinued
6 h before a study visit.
Assessments and outcome measures
Safety and efficacy were assessed during study visits at
baseline and at Weeks 1, 12, 24, 36, 48, and 52 of the
double-blind treatment period. Safety was assessed
through reporting of adverse events (AEs), clinical labora-
tory tests, vital signs, physical examinations, and electro-
cardiograms (ECGs). An AE was classified as treatment-
emergent (TEAE) if it started on or after the date of the first
dose of treatment or if it started before the first dose but
continued with increasing severity during the study, up to
30 days after the last treatment dose. Standardized spiro-
metric measurements of lung function [17] were conducted
at each visit predose (at 45 min and 15 min) and post-
morning dose (at 0.5, 1.0, 2.25, and 3.0 h). Health status
was assessed at all study visits (except Week 1) using St.
George’s Respiratory Questionnaire (SGRQ). Rescue medi-
cation use was recorded daily using a paper diary, with
baseline use assessed during the 1-week period before
treatment initiation.
Key efficacy outcomes included change from baseline to
Week 52 in morning predose (trough) FEV1 (calculated as
the average of the two greatest morning predose FEV1
values) and peak FEV1 (maximum FEV1 reading observed
3 h postmorning dose). Other outcomes included the
change from baseline in SGRQ total and domain scores
(symptoms, activity, and impact), the proportion of pa-
tients who achieved a clinically important improvement in
the SGRQ total score (defined as a decrease of 4 points
[18]), and rescue medication use during the treatment
period.
Statistical analysis
Safety results were summarized descriptively, based on the
safety population, which was defined as all randomized
patients who took 1 dose of study medication. All efficacy
analyses were based on the intent-to-treat (ITT) popula-
tion, which was defined as all randomized patients who
took 1 dose of study medication and had a baseline and at
least one postbaseline FEV1 assessment; missing data were
imputed by the last-observation-carried-forward (LOCF)
approach. Bronchodilation and health status outcomes
were analyzed using an analysis of covariance (ANCOVA)
model with treatment group and sex as factors and corre-
sponding baseline values and age as covariates. Rescue
medication outcomes were analyzed similarly, but used
only treatment group and baseline value as factor and co-
variate, respectively. The sample size of at least 600 pa-
tients from 1200 patients screened was based on the
objective of obtaining long-term safety data; it was notderived through an analysis of statistical power to meet
efficacy objectives as these were considered exploratory.
As such, no statistical comparisons were made between the
treatment groups.
Results
Study population
From the 605 patients with moderate-to-severe COPD who
were randomized to twice-daily aclidinium 200 mg or 400 mg
in this study, 602 patients received at least 1 dose of study
treatment and were included in the safety population. Of
these 602 patients, 600 had a baseline and 1 postbaseline
FEV1 assessment and were included in the ITT population
for efficacy analyses. Baseline demographics were gener-
ally similar between the treatment groups (Table 1). A
similar percentage of patients in each treatment group
completed the 52-week study (200 mg, 57.4%; 400 mg,
55.3%), with withdrawal of consent as the most frequent
reason for discontinuation (Fig. 1).
Safety
The percentage of patients reporting any TEAE was similar
for aclidinium 200 mg (62.4%) and 400 mg (66.0%); most
TEAEs were mild to moderate in severity. COPD exacerba-
tion was the most common TEAE and was reported by
comparable proportions of patients between the treatment
groups (Table 2). Other commonly reported TEAEs (3% in
total patient population) included nasopharyngitis, cough,
sinusitis, headache, nausea, and upper respiratory infec-
tion, none of which appeared to be dose dependent. Diar-
rhea, dry mouth, back pain, and arthralgia were reported
by a greater percentage of patients in the aclidinium 400 mg
group compared with the lower dose (>1% vs 200 mg group),
all of which were reported by <4% of patients for any event
for either dose (Table 2). Diarrhea was considered by in-
vestigators to be treatment related in only 1 patient (0.3%)
in the 400 mg group. Dry mouth was considered treatment
related in all but 1 patient in the 200 mg group. None of the
back pain and arthralgia events were considered treatment
related for either dose.
Adverse events typically reported with anticholinergic
treatment were infrequent and reported by <3% of patients
in either treatment group. Of the 14 patients who reported
constipation in this study, this AE was considered treatment
related in only 1 patient (400 mg), and was considered
moderate and led to study discontinuation. Severe con-
stipation was reported in 2 patients in the aclidinium 200 mg
group, neither of which resulted in treatment discontinu-
ation. The percentage of patients reporting dry mouth was
low (<3% for either treatment group; Table 2), most of
which were considered treatment related but none were
considered severe. A similarly low percentage of patients
reported urinary tract infections (<3%), none of which were
considered treatment related. None of the reports of dry
mouth or urinary tract infection were considered serious or
led to study discontinuation. The overall incidence of
tachycardia was low and occurred in 3 patients (1.0%) in the
200 mg group; none were reported in the 400 mg group.
Figure 1 Study flow chart.
Table 1 Demographic and baseline characteristics.a
Characteristic Aclidinium 200 mg Aclidinium 400 mg Total
n Z 311 n Z 291 N Z 602
Age, mean (SD), years 63.0 (9.5) 64.2 (9.9) 63.6 (9.7)
Male, n (%) 184 (59.2) 167 (57.4) 351 (58.3)
Caucasian, n (%) 282 (90.7) 272 (93.5) 554 (92.0)
BMI, mean (SD), kg/m2 27.4 (5.4) 27.5 (5.3) 27.4 (5.4)
Current smoker, n (%) 164 (52.7) 146 (50.2) 310 (51.5)
Smoking history, mean (SD), pack-years 53.9 (26.7) 54.7 (31.1) 54.3 (28.9)
Baseline concomitant ICS use, n (%) 95 (30.5) 105 (36.1) 200 (33.2)
Postbronchodilator FEV1, mean (SD),
% of predicted value
53.3 (13.4) 51.2 (12.9) 52.3 (13.2)
Postbronchodilator FEV1/FVC, mean (SD), % 50.9 (11.0) 49.5 (11.3) 50.3 (11.2)
Bronchial reversibility,b mean (SD), % 14.8 (14.1) 15.3 (15.5) 15.0 (14.8)
Baseline FEV1,
c mean (SD), L 1.44 (0.57) 1.37 (0.61) 1.41 (0.59)
SGRQ total score,c mean (SD) 48.5 (17.8) 49.8 (18.9) 49.2 (18.4)
Rescue medication use,c mean (SD), puffs/day 2.8 (3.0) 2.9 (3.2) 2.9 (3.1)
BMI, body-mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; SD, standard
deviation; SGRQ, St. George’s Respiratory Questionnaire.
a Safety population at Visit 1 (enrollment) unless otherwise indicated.
b Calculated as % change Z 100  ([postbronchodilator FEV1]  [prebronchodilator FEV1])/(prebronchodilator FEV1).
c Intent-to-treat population at Visit 2 (randomization).
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Table 2 Treatment-emergent adverse events (TEAEs) reported by 2% of patients in any treatment group (safety population).
Preferred term Aclidinium 200 mg
n Z 311
Aclidinium 400 mg
n Z 291
Total
N Z 602
At least 1 TEAE 194 (62.4) 192 (66.0) 386 (64.1)
COPD exacerbation 60 (19.3) 58 (19.9) 118 (19.6)
Nasopharyngitis 15 (4.8) 13 (4.5) 28 (4.7)
Cough 14 (4.5) 11 (3.8) 25 (4.2)
Sinusitis 12 (3.9) 12 (4.1) 24 (4.0)
Headache 11 (3.5) 11 (3.8) 22 (3.7)
Nausea 13 (4.2) 7 (2.4) 20 (3.3)
Upper respiratory tract infection 11 (3.5) 8 (2.7) 19 (3.2)
Bronchitis 10 (3.2) 6 (2.1) 16 (2.7)
Diarrhea 6 (1.9) 9 (3.1) 15 (2.5)
Constipationa 9 (2.9) 5 (1.7) 14 (2.3)
Urinary tract infectiona 8 (2.6) 6 (2.1) 14 (2.3)
Pneumonia 7 (2.3) 6 (2.1) 13 (2.2)
Insomnia 8 (2.6) 5 (1.7) 13 (2.2)
Dry moutha 4 (1.3) 8 (2.7) 12 (2.0)
Back pain 2 (0.6) 10 (3.4) 12 (2.0)
Edema peripheral 5 (1.6) 6 (2.1) 11 (1.8)
Arthralgia 3 (1.0) 8 (2.7) 11 (1.8)
Gastroesophageal reflux disease 8 (2.6) 2 (0.7) 10 (1.7)
Dyspnea 8 (2.6) 2 (0.7) 10 (1.7)
Dizziness 8 (2.6) 1 (0.3) 9 (1.5)
Data reported as n (%).
a AEs typically reported with anticholinergic treatment.
Aclidinium 1-year efficacy and safety in COPD 1961Cardiac TEAEs were reported by a greater percentage of
patients in the aclidinium 200 mg group (7.7%) compared
with the 400 mg group (4.1%) (Table 3). The most frequent
cardiac event was coronary artery disease (0.8%), most of
which were mild to moderate in severity. This TEAE was
reported by 5 (1.6%) patients in the aclidinium 200 mg group
alone, 4 of whom had a history of cardiac disorders prior to
study entry. Of the 36 (6.0%) patients in the study who
reported a cardiac TEAE, 6 (1.0%) reported cardiac events
that were considered treatment related. Two were in the
200 mg group (one patient reported both tachycardia and
supraventricular extrasystoles; another patient reported
sick sinus syndrome); 4 were in the 400 mg group (n Z 1Table 3 Treatment-emergent cardiac adverse events reported
Preferred term Aclidinium 200
n Z 311
Any cardiac TEAE 24 (7.7)
Coronary artery disease 5 (1.6)
Acute myocardial infarction 2 (0.6)
Atrial fibrillation 2 (0.6)
Tachycardia 3 (1.0)
Angina pectoris 1 (0.3)
Left/right bundle branch block 1 (0.3)
Ventricular extrasystoles 1 (0.3)
Sinus bradycardia 2 (0.6)
Palpitations 1 (0.3)
Myocardial infarction 2 (0.6)
Extrasystoles 1 (0.3)
Data reported as n (%).each for cyanosis, acute myocardial infarction, atrial
fibrillation, and ventricular extrasystoles). The atrial
fibrillation reported by 1 patient in the 400 mg group was
severe and the only treatment-related cardiac AE that led
to treatment discontinuation. Medical histories for these
patients who reported cardiac TEAEs that were considered
treatment related included myocardial infarction, coronary
artery disease, atrioventricular block first degree, and
hypertension.
Serious AEs (SAEs) were reported by a similar percentage
of patients in both treatment groups (200 mg, 9.3%; 400 mg,
10.0%). The most commonly reported SAE was COPD exac-
erbation (200 mg, 1.6%; 400 mg, 2.1%); all other SAEs wereby 2 patients in the total population (safety population).
mg Aclidinium 400 mg
n Z 291
Total
N Z 602
12 (4.1) 36 (6.0)
0 (0) 5 (0.8)
2 (0.7) 4 (0.7)
2 (0.7) 4 (0.7)
0 3 (0.5)
2 (0.7) 3 (0.5)
2 (0.7) 3 (0.5)
2 (0.7) 3 (0.5)
0 (0) 2 (0.3)
1 (0.3) 2 (0.3)
0 (0) 2 (0.3)
1 (0.3) 2 (0.3)
Figure 3 Mean (SE) change from baseline in peak FEV1 by
study visit.
1962 A.F. Gelb et al.reported by less than 1% of patients in either treatment
group. One patient in the aclidinium 400 mg group with a
history of coronary artery disease, coronary bypass surgery,
and hypertension reported a severe, transient ischemic
attack that was considered serious but not related to
treatment.
COPD exacerbation was the most frequently reported
TEAE leading to study discontinuation, which was observed
in similar percentages of patients for either dose (Fig. 1).
All other AEs resulting in discontinuation were single oc-
currences in either treatment group. Two patients died
during the double-blind treatment period or within 30 days
after the last dose of study treatment (1 due to biliary
sepsis [200 mg] and 1 due to a subarachnoid hemorrhage
[400 mg]). One patient in the aclidinium 200 mg group died
more than 30 days after the last aclidinium dose due to
malignant lung neoplasm that was diagnosed while the
patient was receiving study treatment. None of the deaths
were considered by investigators to be related to study
treatment. Changes from baseline in clinical laboratory
values, vital signs and ECG parameters were similar be-
tween treatment groups and not considered to be of clin-
ical concern.
Lung function
Mean improvements from baseline in trough FEV1 were
observed during the first assessed time point at Week 1
(200 mg, 64 mL; 400 mg, 91 mL), with maximum improve-
ments of 64 mL (Week 1) and 101 mL (Week 24) for the
200 mg and 400 mg doses, respectively, during the 1-year
study (Fig. 2). The improvements in trough FEV1 observed
at the beginning of the study were generally maintained
until study end with the aclidinium 400 mg dose, with mean
changes from baseline in trough FEV1 of 72 mL after 52
weeks of treatment. Trough FEV1 also remained improved
from baseline after 1 year of treatment with aclidinium
200 mg, albeit with a numerically lower magnitude (34 mL)
compared with the higher dose.
Changes from baseline in peak FEV1 after the first dose
on Day 1 of treatment with aclidinium 200 mg and 400 mg
reached 226 mL and 235 mL, respectively (Fig. 3). TheseFigure 2 Mean (SE) change from baseline in trough FEV1 by
study visit.improvements were generally maintained until study end
(200 mg, 185 mL; 400 mg, 214 mL). Numerically greater
improvements were observed with the 400 mg dose
compared with the 200 mg dose for all lung function efficacy
endpoints throughout the study, demonstrating a dose-
dependent effect on bronchodilation throughout 1 year of
treatment.
Health status and rescue medication use
Clinically important improvements in SGRQ total scores
(4-point improvement from baseline) were observed at all
study visits throughout the 52-week treatment period with
aclidinium 200 mg and 400 mg (Fig. 4). The mean improve-
ment from baseline in SGRQ total score was 5.3 units
(200 mg) and 5.2 units (400 mg) at study end (Week 52). The
improvements from baseline in each of the 3 SGRQ domain
scores for the 400 mg dose throughout the study ranged
from 5.8e7.6 units for symptoms, 3.8e5.5 units for activity,
and 5.5e7.1 units for impact. These were comparable to
the improvements observed with the 200 mg dose (6.6e9.1Figure 4 Mean (SE) change from baseline in SGRQ total score
by study visit.
Aclidinium 1-year efficacy and safety in COPD 1963units, 4.3e5.4 units, and 4.9e6.2 units, for each of the
domains, respectively).
The percentage of patients who achieved a clinically
important improvement in SGRQ total score (ie, 4 units)
ranged from 41.6% to 46.6% for aclidinium 200 mg and from
45.2% to 49.1% for aclidinium 400 mg at all study visits. The
percentage of patients who achieved a clinically important
improvement in SGRQ total score was numerically higher in
the aclidinium 400 mg group compared with the 200 mg
group throughout the study. Rescue medication use during
the overall treatment period was 1.5 puffs/day (200 mg) and
1.4 puffs/day (400 mg), which was approximately one-half
of the baseline value (Table 1).Discussion
COPD is a treatable, but only partially reversible, disease
warranting continued maintenance treatment for effective
management. As patients with COPD tend to be elderly,
have various comorbidities, and receive multiple medica-
tions, evaluating the long-term safety and tolerability of
any new pharmacological treatment is an especially
important step in assessing its potential for disease man-
agement [7,8]. Furthermore, patients with COPD are often
diagnosed with comorbidities such as cardiovascular dis-
ease [19e21], making it critical to evaluate cardiac safety
of any new potential treatment for this disease.
The current study demonstrates that long-term treat-
ment with twice-daily aclidinium was well tolerated by
patients with moderate-to-severe COPD throughout the 52-
week treatment period, with similar safety profiles be-
tween both doses. Anticholinergic TEAEs such as dry mouth
and constipation, which are typically reported with LAMA
treatment, were reported by a low percentage of patients
treated with aclidinium (<3% for any specific event with
either aclidinium dose). Similarly, any specific cardiac TEAE
was reported by 1% of patients with either aclidinium
dose, with a total of 6% of patients in the entire safety
population reporting any cardiac event. There was no
apparent dose-dependent increase in the percentages of
patients reporting any individual anticholinergic or cardiac
event, with the exception of dry mouth; none of the dry
mouth events were considered severe or serious. The
tolerability of aclidinium may be due to its rapid plasma
hydrolysis [14,22e24], which suggests that treatment with
the drug may lead to fewer systemic side effects. The
safety and tolerability observed with long-term aclidinium
treatment in this study are consistent with the safety pro-
files reported in previous Phase 3 studies with twice-daily
aclidinium up to 24 weeks [10,11], suggesting that there
is no increase in safety concerns with longer aclidinium
treatment. In addition, it has been previously reported that
a total daily dose of aclidinium 800 mg administered for 3
days in healthy subjects did not show any significant effect
on QT interval [25], similar to the lack of clinically relevant
changes from baseline in ECG parameters with aclidinium
treatment in the current 1-year study. However, given the
concern regarding cardiovascular adverse events with
muscarinic bronchodilators [26e29] and the prevalence of
cardiovascular comorbidities in patients with COPD [30,31],
a study is planned to more thoroughly evaluatecardiovascular safety of aclidinium treatment in COPD pa-
tients who may be at greater risk for cardiovascular adverse
events.
This study also demonstrates that 52-week treatment
with twice-daily aclidinium provides improvements in lung
function and health status in patients with COPD. Patients
treated with aclidinium experienced improvements from
baseline in lung function as early as Day 1, the first time point
assessed for peak FEV1, and Week 1, the first time point
assessed for trough FEV1, that were generally maintained
until study end. The 400 mg dose consistently provided
numerically greater improvements in bronchodilation
compared with the lower dose throughout the 52-week
treatment period. The lung function results from this long-
term study are thus in accordance with previous 12- and 24-
week studies that evaluated twice-daily aclidinium 200 mg
or 400 mg in patients with COPD; these studies demonstrated
significant improvements in bronchodilation on Day 1 which
were maintained over the treatment period, with a numeri-
cally greater magnitude of improvement observed with the
higher dose [10,11]. The maximal bronchodilation observed
soon after treatment initiation with aclidinium is consistent
with the previously reported achievement of a pharmacoki-
netic steady state of twice-daily aclidinium doses up to
800 mg by 2 days after dose administration [24], in contrast to
the 2e3 weeks reported for tiotropium 18 mg [32,33]. Since
delayed onset of action following dosing is associated with
poor adherence to treatment regimens [34,35], the rapid
onset of improvement seen with aclidinium treatment may
improve patient adherence.
The GOLD guidelines emphasize that treatment of stable
COPD should include managing symptoms and improving
health status in addition to improving lung function [5].
Clinically important improvements in SGRQ total scores
were observed with aclidinium treatment throughout this 1-
year study. These were similar in magnitude to the changes
from baseline in SGRQ total scores with twice-daily aclidi-
nium 200 mg and 400 mg treatment reported in a 6-month
study but did not reflect the dose separation observed in
that earlier trial [10]. Nevertheless, the current study also
showed that long-term treatment with aclidinium was
associated with a reduction in rescue medication use,
similar to the results of earlier studies of shorter duration
[10,11], further supporting the positive effect of aclidinium
on health status and symptom management.
One limitation of this study is that a placebo arm was not
included; therefore, no adjustments for placebo on outcome
measures were possible. Without treatment, an annual
decline in trough FEV1 of 47e79 mL is expected in patients
withGOLD stage II or III COPD, according to a recent reviewof
large placebo-controlled COPD studies [36]. As the im-
provements in trough FEV1 shown here were changes from
baseline values and could not take into account thedecline in
trough FEV1 that is typically seen in COPD patients over time,
the magnitudes of improvements seen in this study could
potentially have been greater if comparisons to a placebo
group had been possible. Another limitation is the absence of
an active comparator, which prevents a direct comparison of
the efficacy of long-term use of aclidinium compared with
those of other bronchodilators.
Overall, this study demonstrated that long-term treat-
ment with twice-daily aclidinium was well tolerated, with
1964 A.F. Gelb et al.no clinically meaningful differences in safety profiles be-
tween the two doses and a greater magnitude of improve-
ment in bronchodilation observed with the 400 mg dose
compared with the lower dose. Improvements in lung
function, observed as early as the first day of aclidinium
treatment, were accompanied by improvements in health
status and reductions in rescue medication use that were
generally maintained throughout the 1-year study. These
results thus support the use of twice-daily aclidinium 400 mg
as an effective new maintenance treatment option for
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